Shilpa Medicare Reports Strong Q4 Results Amid Improved Profitability and Efficiency Metrics

Shilpa Medicare, a midcap player in the Pharmaceuticals & Drugs industry, has recently reported its financial results for the quarter ending December 2024. The evaluation changes reflect a notable shift in the company's score, which has moved to 30 from 28 over the past three months.
The financial data reveals several positive trends for Shilpa Medicare. The operating profit to interest ratio has reached its highest level at 6.87 times, indicating an enhanced capacity to manage interest payments. Profit Before Tax (PBT) has shown significant growth, recorded at Rs 40.48 crore, which is a substantial increase compared to the average of the previous four quarters. Similarly, Profit After Tax (PAT) stands at Rs 31.78 crore, marking a remarkable rise over the same period.

Additionally, the inventory turnover ratio has improved, reaching 3.72 times, suggesting that the company is effectively managing its inventory. The Earnings per Share (EPS) has also peaked at Rs 3.25, reflecting increased profitability. Furthermore, the debt-equity ratio is at its lowest in recent periods, indicating a reduction in borrowing relative to equity.

However, it is important to note that cash and cash equivalents have reached a low of Rs 17.17 crore, signaling a decline in short-term liquidity.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.